Prof. Hao received her PhD degree in 2007 at Sichuan University of China then completed the postdoc training in Prof. Zhan’s lab, University of Iowa, USA. The main emphasis of her research is to identify the pathogenesis of multiple myeloma and Waldenström macroglobulinemia. Multiple Myeloma is a heterogeneous disease with a complex genetic landscape, characterized by several numerical and structure aberrations. Despite proteasome inhibitors (PIs) have transformed management of multiple myeloma (MM) and improved the outcome of patients, MM still incurable. Drug resistance remains the key problem and causes refractory and relapsed in MM. The research interesting of Prof. Hao is focus on the functional investigation of oncogene and non-coding RNAs involved in myeloma development and drug resistance. Another is focus on the tumor microenvironment interaction with tumor cells in the pathogenesis and progression of multiple myeloma.
Waldenström macroglobulinemia (WM) is a rare and incurable indolent B-cell malignancy. The molecular pathogenesis and the role of the immunosuppressive microenvironment in WM development remain incompletely understood. Her study demonstrated that comparative microarray profiles provided more comprehensive insights into the biology of WM. The findings presented here have implications for the advancement of novel therapies, such as targeting aberrant T-cell markers in WM. Her study facilitates further comprehension of the biological heterogeneity of tumor cells and the immunosuppressive microenvironment in WM. These findings may have implications for the development of innovative immunotherapies, such as targeting pre-exhausted CD8-T cells in WM.
Her study on this project address whether increased tumor suppressor microRNA expression results in proliferation inhibition of myeloma cells by in vitro and in vivo model, and by performing microRNA array to evaluate whether circulating microRNA can be used as a biomarker for myeloma and myeloma related bone disease identification. During the period of her postdoc training, her major project is to identify whether increased NEK2 expression results in increases bone destruction in myeloma by 5TGM1 and NSG mouse models, and by GEP array, TAP/MS and ChIP assay to address the molecular mechanisms mediated by NEK2 in myeloma bone disease.
Postdoctoral Fellow, Multiple Myeloma Research and Treatment Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA, 2014-2016
PhD, Immunology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan, China, 2004-2007
MS, Immunology, Department of Basic Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, China, 2001-2004
BS, Clinical Medicine, Department of Clinical Medicine, Guizhou Medical University, Guiyang, Guizhou, China, 1996-2001
Principal Investigator, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2018-Present
Professor, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2016-
Associate Professor, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2015-2016
Postdoctoral Fellow, Myeloma Research and Treatment Center, Carver College of Medicine, University of Iowa, USA, 2014-2016
Associate Professor, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2011-2013
Assistant Professor, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2007-2011
PRINCIPAL HONORS, AWARDS:
2021 First Prize, Tianjin Science and Technology Progress Award (Ranked 3rd)
2018 Second Prize, Outstanding Achievement Award for Research in Institutes of Higher Education (Science and Technology), Ministry of Education of China (Ranked 2nd)
2015 ASH Annual Meeting Oral Presentation Traveling Award, American Society of Hematology
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
Standing Committee Member and Deputy Secretary-General, Myeloma Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Member, Hematological Immunology Committee, Chinese Society for Immunology
Member, Geriatrics Committee, China Association of Gerontology and Geriatrics
Standing Committee Member, Hematologic Oncology Committee, Tianjin Anti-Cancer Association
Member, Translational Medicine Committee, Tianjin Anti-Cancer Association
Council Member, Tianjin Pharmacological Society
Youth Editorial Board Member, Chinese Journal of Hematology
Editorial Board Member, Cancer Biology & Medicine
Review Editor, Frontiers in Oncology
SELECTED PUBLICATIONS:
1. Liu L, Sun H, Feng F, Sun X, Ma J, Lv R, Yu T, Ye L, Li X, Yu Z, Zhang X, Jing H, Yao Y, Ma F, Qiu L*, Hao M *. Improving predictive accuracy in multiple myeloma through the utilization of a plasma cell profile derived from single-cell RNA sequencing. Haematologica. 2025 May 22, Accepted.
2. Fang T, Liu L, Sun H, Zhang X, Sun X, Yu Z, Gong L, Xie S, Zhao Y, Li Y, Qiu L, An G, He B*, Hao M*. A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28. Biomark Res. 2025 Apr 7;13(1):57. doi: 10.1186/s40364-025-00773-3.
3. Yan W, Qiu C, Zhou J, Xu J, Cui J, Liu Y, Du C, Yu T, Zhang S, Sui W, Deng S, Xu Y, Zou D, Yuan W, Qiu L, Hao M*, Chu Y*, An G*. The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma. Haematologica. 2025 Apr 24. doi: 10.3324/haematol.2025.287523.
4. Yan W, Zhou J, Liu Y, Xu J, Cui J, Du C, Zhang S, Lv R, Sui W, Deng S, Xu Y, Yi S, Zou D, Hao M, Qiu L, An G. The Monoclonal Gammopathy of Undetermined Significance-Like (MGUS-like) Classifier Stratifies Prognosis in Multiple Myeloma: Results from Real-World Data in Chinese Population. Clin Lymphoma Myeloma Leuk. 2025 Mar 9:S2152-2650(25)00081-3. doi: 10.1016/j.clml.2025.03.002. Epub ahead of print. PMID: 40157884.
5. Gong LX#, Sun H#, Liu LT, Sun XY, Fang T, Yu Z, Sui WW, Xu JY, Wang TY, Feng FS, Lei L, Rui W, Liu YX, Zhao XQ, An G, Lin X, Qiu LG, Hao M*. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma. Haematologica, 2024, May.
6. Px T, Z Y, Hao S, Lt Liu, Lx G, Teng F, Xy S, Sy Xie, Gang An, Zs Xu, Lg Qiu, M Hao*. CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy. EBioMedicine. 2024 Feb;100:104961.
7. Gong L, Qiu L, Hao M*. Novel Insights into the Initiation, Evolution, and Progression of Multiple Myeloma by Multi-Omics Investigation. Cancers (Basel). 2024 Jan 24;16(3):498.
8. Fang T, Sun H, Sun X, He Y, Tang P, Gong L, Yu Z, Liu L, Xie S, Wang T, Xu Z, Yi S, An G, Xu Y, Zhu G, Qiu L, Hao M*. Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma. Blood Sci. 2023 May 11;5(3):196-208.
9. Wei XJ; Yu Z; Tang PX; Sun H; Gong LX; Liu LT; Fang T; He Y; Wang TY; Sui WW; Xu Y; An G; Xu ZS; Ma XK; Qiu LG; Hao M*; Multiple myeloma–derived miR-27b-3p facilitates tumour progression via promoting tumour cell proliferation and immunosuppressive microenvironment, Clinical and Translational Medicine, 2023, 13.
10. Yu Z, Wei X, Liu L, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y, Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L, Hao M*. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 2022; 78:103950.
11. Sun H; Fang T; Wang TY; Yu Z; Gong LX; Wei XJ; Wang HJ; Liu LT; Yan YT; Sui WW; Xu Y; Yi SH; Qiu LG; Hao M*; Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia, J Transl Med., 2022, 20(1): 576-587.
12. Lv JQ; Sun H; Gong LX; Wei XJ; He Y; Yu Z; Liu LT; Yi SH; Sui WW; Xu Y; Deng SH; An G; Yao Z; Qiu LG; Hao M*; Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma, Frontiers in Immunology, 2022, 13(1).
13. Liu L, Yu Z, Cheng H, Mao X, Sui W, Deng S, Wei X, Lv J, Du C, Xu J, Huang W, Xia S, An G, Zhou W, Ma X, Cheng T, Qiu L, Hao M*. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment. Sci Rep. 2020 Nov 25;10(1):20508.
14. Yu T, Du C, Ma X, Sui W, Yu Z, Liu L, Zhao L, Li Z, Xu J, Wei X, Zhou W, Deng S, Zou D, An G, Tai YT, Tricot G, Anderson KC, Qiu L, Zhan F, Hao M*. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 Jul;18(7):1063-1073.
15. Li Z, Liu L, Du C, Yu Z, Yang Y, Xu J, Wei X, Zhan F, Lai Y, Qiu L, Hao M*. Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma. Cancer Gene Ther. 2020 Jan 28.
16. Hao M, Barlogie B, Tricot G, Liu L, Qiu L, Shaughnessy JD Jr, Zhan F*. Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of Waldenström's Macroglobulinemia. Clin Cancer Res. 2019 Jan 1;25(1):201-209.
17. Franqui-Machin R, Hao M (co-first authors), Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F*. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 Jul 2;128(7):2877-2893.
18. Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F*. NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. Leukemia. 2017 Jul;31(7):1648-1650.
19. Hao M, Zang M, Zhao L, Deng S, Xu Y, Qi F, An G, Qin Y, Sui W, Li F, Yang W, Li Z, Yi S, Zou D, Zhan F, Qiu L *. Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. Oncotarget. 2016 Apr 12;7(15):19589-600.
20. Li F, Xu Y, Deng S, Li Z, Zou D, Yi S, Sui W, Hao M*, Qiu L. MicroRNA-15a/ 16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 2015 Nov 10;6(35):38270-82.
21. Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D, Li F, Qi F, Zhang Y, Yang Y, Zhan F, Qiu L*. Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2015 Apr 15;136(8): 1835-44.
22. Hao M, Zhang L, An G, Sui W, Yu Z, Zou D, Xu Y, Chang H, Qiu L*. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011 Sep 22;4:37.
23. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H, Qiu L*. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011 Sep;52(9):1787-94.